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The  mononuclear  phagocyte  system  constitutes  an  important  element  of the 
immune  defenses of the  host  against  neoplasia  (reviewed  in  [1-5]).  Mononuclear 
phagocytes activated for cytolysis by agents such as bacillus Calmette-Gu~rin (BCG), 1 
though not macrophages from most sites of inflammation induced by sterile phlogistic 
agents, efficiently lyse tumor target cells in vitro (reviewed in [5-8]). The cytolysis is 
target selective in that activated macrophages usually destroy neoplastically trans- 
formed  cells  to  a  greater  extent  than  their  nontransformed  counterparts  (5-8). 
However, the basis of this discriminatory cytolysis is poorly understood. Cytolysis by 
activated macrophages has generally been found to be contact-dependent (5-8), and 
cinemicrographic  studies  have  demonstrated  that  activated  macrophages  interact 
extensively and  intimately with  the  surface  of neoplastic,  but  not  nonneoplastic, 
targets (9-11).  Recently, observations made with two distinct experimental systems 
have indicated the intimate contact between macrophages and targets represents firm 
physical binding of neoplastic targets to the surface of activated macrophages  (12, 
13). The binding, which has the same selectivity as eytolysis in regard to both type of 
macrophage and type of target (12,  13), has subsequently been shown to be an initial 
and necessary event in macrophage-mediated cytolysis (14, 15). The binding of tumor 
cells to activated macrophages may thus represent a  part of the sensory mechanism 
by which mononuclear phagocytes discriminate between neoplastic and nonneoplastic 
cells. However, the basis of selective target binding by activated macrophages has not 
yet been established. This report  presents evidence that membrane preparations of 
three murine, nonadherent neoplastic cells, but not of lymphocytes, contain structures 
that inhibit the binding of intact homologous and heterologous neoplastic targets to 
BCG-activated murine maerophages. 
Materials and Methods 
Mice.  Inbred C57BL/6J mice (The Jackson Laboratories, Bar Harbor, Maine) of 8-12 wk 
of age were used in all experiments. 
Tissue Culture.  Cell lines were maintained in Eagle's minimum essential medium (Grand 
* Supported in part by grants CA-16784, CA-14236, AI-08897, and ES-07031 and by contract CB-74152 
from the National Cancer Institute. 
1 Abbreviations used in this paper." BCG,  bacillus  Calmette-Gu~rin; FCS,  fetal  calf serum; HBSS,  Hanks' 
balanced salt solution;  TG, thioglycollate broth. 
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Island  Biological Co.,  Grand  Island,  N.  Y.)  supplemented  with  fresh  glutamine  (2  mM), 
penicillin (125  U/ml),  streptomycin (62.5  /.tg/ml), plus  10%  fetal calf serum  (FCS)  (Sterile 
Systems, Inc., Logan, Utah) as previously described (13). Washes of targets and macrophages 
were performed in Hanks' balanced salt solution (HBSS) (Microbiological Associates, Walkers- 
ville,  Md.)  containing  5%  FCS.  All  tissue  culture  media,  sera,  reagents,  and  membrane 
preparations were endotoxin-free (defined as containing <0.4 ng/ml ofendotoxin, as quantified 
by the Limulus amebocyte lysate (Cape Cod Associates, Woods Hole, Mass) assay. 
Target Cells.  The origin of the target cells employed (the EL-4 lymphoma from C57BL/6J 
mice, the RLol leukemia from BALB/c mice, and the P815 mastocytoma from DBA/2 mice) 
have been  previously described (13).  Cell lines were maintained in vitro as described (13). 
Normal splenic lymphocytes were obtained from unimmunized C57BL/6J mice and prepared 
as  previously  described  (13).  To  examine  rapidly  dividing nonneoplastie  targets  as  well, 
lymphoblasts were induced in splenic lymphocytes by lipopolysaccharide from Escherichia coli 
055:B5 (LPS) (10 #g/ml; Difco Laboratories, Inc., Detroit, Mich.) for 48 h of culture in RPMI- 
1640 supplemented with nonessential amino acids, sodium pyruvate, and 5% FCS. The resultant 
cultures of lymphoblasts, which contained >80%  blast forms as determined by microscopy, 
were bound to a slightly greater extent and were iysed to the same extent as normal iymphocytes 
by BCG maerophages (see Table I, footnote § and Table III, footnote  I[ ). Lymphocytes and 
lymphocyte-membrane preparations were thus employed as controls in subsequent experiments. 
Reagents.  Brewers' thioglycollate  broth (TG), prepared according to manufacturer's instruc- 
tions, was obtained from Difco Laboratories, Inc.  (catalogue No. B236).  BCG, Phipps strain 
1029, was purchased from the Trudeau Institute, Saranac Lake, N. Y. Na2[SICr]O4  (sp ae: 50- 
400 #Ci/mg) was purchased from Amersham Searle Inc., Chicago, Ill. 
Macrophages.  Peritoneal macrophages were elicited in C57BL/6J  mice by BCG and TG as 
previously described (16). The peritoneal exudate cells obtained 3 d after inoculation of these 
phlogistic agents were plated to result in uniform densities of 2.5 ×  105 adherent macrophages/ 
cm  2. After 3 h, the wells were washed vigorously four times to result in monolayers of purified 
macrophages (>99%), as judged morphology, staining for nonspecific esterase, and phagocytic 
uptake of IgG-coated erythroeytes (17). 
Preparation of Membranes.  Crude membrane preparations of EL-4, P815, and RLol tumor 
targets and of normal lymphocytes were prepared as previously described (18).  Briefly, 1.0 × 
10 l° targets were lysed by freezing and thawing in Tris-buffered saline (0.15 M  NaCI and 0.01 
M Tris, pH 8.3). The resultant suspension was centrifuged at 300 g for 12 min at 4°C to remove 
nuclei and heavy cellular debris. The crude membrane preparation was pelleted at  100,000 g 
for 60  min  at  4°C,  resuspended  in  the Tris-sodium chloride buffer,  and  pelleted again at 
100,000 g. The precipitate was resuspended in HBSS. Protein concentration of the suspended 
membrane preparation was determined by the method of Lowry et al. (19).  The suspension 
was divided into aliquots, which were stored at -20°C. After thawing for use, the membrane 
preparations were sonicated (30 s in a Cole-Parmer ultrasonicator, model 8845-30, Cole-Parmer 
Instrument  Co.,  Chicago,  Ill.)  to  disperse any  large  aggregates present.  The  membranous 
character of each batch of membranes, after sonication, was verified by electron microscopy. 
To obtain membrane preparations enriched in plasma membranes, we employed the method 
of Crumpton and Snary (20). In brief, 2 ×  10 l° EL-4 cells were disrupted by brief sonication in 
a bath-type sonicator, and nuclei were removed from the preparation by centrifugation at 300 
g for 10 min at 4°C. The mitochondrial fraction was removed by centrifuging at 4,000 g for 15 
min, and the microsomal pellet was obtained by centrifuging the supernate at 20,000 g for 30 
min. After one wash, the microsomal fraction was resuspended in 36% sucrose (10 mM Tris- 
HCI, pH 7.5), overlaid with 25% sucrose and centrifuged at 87,000 g for 18 h. The interfacial 
band from the gradient was recovered and, after homogenization in a Dounce homogenizer in 
the buffer, was twice sedimented by centrifugation at 75,000 g for 20 min at 4°C. The resultant 
pellet was enriched in plasma membranes, as indicated by a  15-fold increase in serologically 
detectable H-2  activity (18)  per microgram protein over the crude membrane preparations 
described above. 
Labeling of Targets.  The  P815,  EL-4,  RLol  and  lymphocytic targets were  labeled with 
Na2[SlCr]O4  as previously described (13) to yield 6 X  10s-10 ×  10  a cpm/10  s targets, 
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(13). At the time of binding (4 h  after explantation of the macrophages), most of the BCG- 
activated and TG-elicited macrophages are well  spread and spread to an equal degree (13). 
Binding of the  neoplastic  targets  is  most consistently observed  to those  BCG macrophages 
which  are  well  spread,  when  observed  by either  phase-contrast  microscopy (13),  scanning 
electron microscopy (13), or cinemicroscopy (C. Stewart, P. Marino, and D. Adams, unpublished 
observations).  To conserve the amounts of membrane preparation  employed, the assay was 
conducted in fiat-bottomed, 6-mm microtiter wells (73-003-05;  Linbro Chemical Co., Hamden, 
Conn.). In brief, wells containing a constant density of purified macrophages (2.5 ×  105 Mob/ 
cm  2 or a  total of 7.2  ×  104 macrophages/well)  were cocuhivated with single-cell  suspensions 
containing 7.5 X 104 targets previously labeled with Na2151Cr]O4. The cultures were incubated 
at 37°C under 5% COs for 1 h, after which, the targets were removed by aspiration and four 
vigorous, uniform washes with a plunger-type pipette. Under these conditions, the number of 
residual targets, >99% of which are adherent to macrophages, is uniform from well to well as 
determined by microscopic examination of  the cultures (13). Furthermore, the neoplastic targets 
are so firmly attached to the BCG-activated macrophages that >10  -s dyn of force is required 
to disrupt the binding, when strength of binding is determined by the method of McClay et al. 
(21). By contrast, loosely adherent targets, which can be detached by <10  -n dyn of force, are 
readily removed by the four washes. 
The remaining label was solubilized and the amount of residual radioactivity determined. 
Binding was calculated by the formula: total number of targets bound 
counts per minute bound to monolayers 
--  ×  7.5 ×  104 
total counts per minute present 
Binding to plastic alone in the absence of macrophages (<7.5 ×  102 tumor targets or <1% of 
total label/well or <20 ×  102 lymphocytes or <3% of total label/well) was determined in each 
experiment and then subtracted from each value to give binding to macrophages (number of 
targets bound to macrophages). 
Assay  for Macrophage-mediated Cytotoxicity.  Macrophage-mediated cytotoxicity was determined 
as previously described  (142, except that experiments were conducted in microtiter wells  (7.5 
×  104 targets plus 7.2 X  10  purified adherent macrophages cultured for 18 h). 
Results 
Effect  of Membrane  Preparations on  Binding.  To  examine  the  possibility  that  the 
structure(s)  mediating  binding was located  in  the  membranes of neoplastic  targets, 
we prepared suspensions of membranes from various targets.  Binding of P815 targets 
to BCG-aetivated  maerophages was inhibited  in a  dose-dependent  fashion by mem- 
brane  preparations  from EL-4, RLol, or P815 neoplastic  targets,  but  not  by mem- 
branes from lymphocytes (Fig.  1 A). At a  concentration of 125/~g of membrane/well, 
binding of P815 targets was inhibited  72-85% by membrane  preparations  from the 
three tumor cells  (Fig.  1 A).  Inhibition of --<93% by this concentration of membrane 
preparation was observed in other experiments (data not shown). Similar results were 
obtained when the same membrane preparations were tested against binding of either 
RLol or EL-4 targets (data not shown). A  concentration of 50/~g of membrane/well, 
representing a  midpoint on the initial linear portion of the inhibition curve (Fig.  1 A), 
was chosen for use in subsequent experiments. 
The binding of neoplastic  targets  to BCG-activated maerophages  is saturable  (5). 
Exposure of BCG-aetivated  macrophages to membrane preparations  from the EL-4 
targets reduced the number of EL-4 targets bound at saturation  but did not prevent 
saturation  of binding  (Fig.  1 B).  Similar  observations  were  made  when  binding  of 
RLal  targets to BCG-activated macrophages was examined  (data not shown). 
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Fro.  1.  (A) Dose-response of inhibitory activity of crude membrane preparations from lymphocyte 
(A) P815 (I-q),  EL-4 (A), and RLol (©) targets on the binding  of 51Cr-labeled P815 targets to BCG- 
activated macrophages  (2.5 x  105 macrophages/cm:').  The membrane preparations of tumor targets 
or splenic lymphocytes  from normal C57BL/6J mice were added to the macrophage cultures over 
a  range of concentrations (10-125  #g/well).  After  1 h,  the cultures were washed  to remove  all 
nonadherent membrane fragments.  Control wells, to  which  no membranes were  added,  were 
similarly washed. The cultures were then challenged with 7.5 ×  104 SlCr-labeled P815 tumor targets. 
The number of P815 targets bound after 1 h of cocultivation was then quantified. Similar data were 
obtained in an additional experiment. (B) Effect of EL-4 membrane preparation on saturation of 
binding of ~lCr-labeled  EL-4  tumor  targets  to  BCG-activated  macrophages.  EL-4  membrane 
preparations (50 #g/well) were added to established cultures of BCG-activated macrophages.  After 
1 h, the cultures were washed to remove the nonadherent membranes; control wells were similarly 
washed. The macrophage cultures were then challenged with various numbers of 51Cr EL-4 tumor 
cells (6.0 ×  104-30.0 X  104). After  1 h of cocultivation, the number of targets  bound to the BCG- 
activated macrophages  were quantified. Binding in EL-4-treated  cultures (0) was compared with 
untreated controls (A). Addition of 50 #g of lymphocyte membranes to similar culture did not result 
in any inhibition of binding of EL-4 targets  to BCG-activated macrophages  (data not shown). 
to  BCG-activated  macrophages  was  inhibited by membrane  preparations  from  the 
heterologous  EL-4 and  P815  targets  as well as by membrane  preparations  from  the 
homologous  targets  (Table  I).  Likewise,  binding  of  EL-4  and  P815  targets  was 
inhibited  by  membrane  preparations  from  heterologous  and  homologous  targets 
(Table I). However,  membrane  preparations of lymphocytes did not inhibit binding 
of any of the three neoplastic targets  to BCG-activated macrophages  (Table I). The 
low level of binding of lymphocytes to BCG-activated macrophages was not inhibited 
by any of the  four membrane  preparations,  including membrane  preparation  from 
lymphocytes  (Table  I).  Finally,  the  low  level  binding  of  RLol,  EL-4,  P815,  or 
lymphocyte  targets  to  TG-elicited macrophages  was  not  significantly inhibited by 
membrane  preparations from any of the four targets  (Table I). 
Adsorption of Inhibitory Activity.  Target binding to macrophages is selective not only 
in regard to type of target bound but in regard to type of macrophage that binds the 
targets  (13). To examine the selectivity of macrophages in interacting with membrane 
preparations,  we  incubated limiting concentrations of membrane  preparations  from 
P815,  EL-4,  and  RLol  targets  with  monolayers  of TG-elicited  or  BCG-activated 
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TABLE I 
Effect of Membrane Preparations on Binding of Homologous and Heterologous Targets by BCG-activated 
Macrophages 
Added  to wells* 
Number of targets bound to macrophages  (percent inhibition):~ 
Lympho-  RLol 
cytes§ 
EL-4  P815 
BCG Me# +  medium  5.0 4- 0.6 
BCG M¢ +  membranes  of lymphocytes  6.5 :t: 1.1 
BCG Mg# +  membranes of RLal  targets  6.5 4- 0.8 
BCG Mt~ +  membranes of EL-4 targets  5.0 4-  1.3 
BCG M~b +  membranes  of P815  targets  6.5:1:0.9 
TG Me +  medium  3.0 4- 0.8 
TG M¢, +  membranes of lymphocytes  3.0 4- 1.1 
TG M~b +  membranes of RLol  5.0 4-  1.0 
TG M,k +  membranes of EL-4  4.0 4-  1.1 
TG M¢ +  membranes of P815  4.0 4-  1.2 
x  10  3 
15.5±  1.1  21.5-+2.1  28,5 +  2.5 
14.5 +  0.7 (--fi%)  19.5 ~  1.7 (--9%)  28,0 +  1.2 (--2%) 
6.5 4-  1.4 (--58%)  12.5  -6  1.1 (--42%)  18.5 4-  1.0 (--35%) 
8.0 4-  1.3 (--48%)  10.5  :~ 0.7 (--49%)  18.0 4-  1.5 (--37%) 
9.5 4- 0.9 (--39%)  14.0 4- 1.4 (--35%)  17.0 4-  1.4 (--40%) 
6.0 4- 0.8  7.0 4- 2.0  9.5 4-  1.8 
5.04-  1.0  4.5:1::  1.8  7.54-  1.1 
4.0 -+ 1.2  3.5 -+ 0.9  7.5 :t:0.7 
4.0 4-  1,0  4.5 4-  1.0  9.0 4-  1.4 
6.54-  1.8  5.5 ;t: 0.5  8.54-  1.1 
* Cultures of BCG-activated or TG-elicited macrophages  (BCG Me and TG M¢, respectively) (2.5 ×  106 macrophages/cm z) were established. 
Medium or membrane  preparation  (50 lag/well)  from various  targets were added  to the cultures.  After  1 fi, the cultures  were washed  to 
remove nonadherent  membranes  and then challenged  with  7.5 x  104 5tOt-labeled  lymphocytes,  RIll,  EL-4, or P815 targets. After  I  h of 
cocuhivation,  the number of targets bound to the BeG M~k was quantified. 
:~ Target  used for quantification  of binding.  Number  of targets  bound  in  thousands  (mean  "+ SEM). Percent  inhibition  as compared  with 
medium  control. Similar results obtained  in four additional experiments. 
§ The binding of lymphoblasts  (Materials  and Methods)  to BCG MO under these conditions was 5.2 +  0.5 x  10  a and 7.0 +  0.6 x  10  a targets 
bound in two similar experiments  (compare to binding of lymphocytes of 5.0 4- 0.6 X  103 (see above) and 6.5 "+ 0.7 ×  10s). 
activity of membrane preparations from P815, EL-4, and RLol cells was removed by 
incubation of the membrane preparations with BCG macrophages  (Table II). Incu- 
bation  of membrane  preparations  with  monolayers  of TG  macrophages,  however, 
removed little of the inhibitory activity  (Table II). 
Effect of Inhibition  of Binding  on Cytotoxicity.  To determine the effect of membrane 
preparations on macrophage-mediated  tumor cytotoxicity, we incubated monolayers 
of BCG-activated macrophages with various membrane preparations for 1 h, removed 
the excess membranes, and challenged the macrophages with intact targets. Exposure 
of the BCG-activated  macrophages to membrane preparations  from RLol, EL-4, or 
P815  targets  inhibited  subsequent  cytolysis  of all  three  of the  targets  (Table  III). 
Exposure of BCG-macrophages  to membrane preparations from lymphocytes did not 
significantly alter the degree of subsequent cytolysis  (Table III). 
Effect of Plasma Membranes on Binding.  To ascertain the locus of inhibitory activity 
in the crude membrane preparations, we examined the effects of preparations enriched 
--15-fold in plasma membranes  (Fig. 2). Preparations enriched in plasma membranes 
from EL-4 targets inhibited binding of homologous EL-4 targets and of heterologous 
P815  targets more effectively than  did crude membrane  preparation  from the EL-4 
targets (i.e., the amount of membrane preparation in/~g of protein required to inhibit 
binding  50% was "10-fold  greater  in the crude membrane  preparation  than  in the 
plasma  membrane  preparation  when the two were tested  against  EL-4 targets  and 
"8-fold greater when the two were tested against  P815 targets). 
Discussion 
Activated mononuclear phagocytes have been observed to lyse neoplastic targets in 
preference to their normal counterparts  in many  laboratories  (reviewed in [5, 6,  14, 
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TABLE  II 
Effect of Adsorption of Membrane Preparations on Monolayers of BCG-activated or TG-elicited 
Macrophages 
Added to wells* 
Number of targets bound to macrophages;~ 
Lympho-  EL-4  RLo 1  P815 
cytes 
BCG Me +  medium  4.5 ± 0.5 
BCG Me +  membranes of lymphocytes  5.3 ±  1.2 
BCG  MO +  membranes of lymphocytes adsorbed to  NT§ 
TG M~ 
BCG MO +  membranes of lymphocytes adsorbed to  NT 
BGG M~ 
BCG M¢ +  membranes of EL-4 targets  5.3 ± 0.5 
BCG Me +  membranes of EL-4  targets adsorbed to  NT 
TG MO 
BCG  Me +  membranes of EL-4 targets adsorbed to  NT 
BCG MO 
BCG M¢ +  membranes of RLol targets  5.3 ± 0.7 
BCG  Me +  membranes of RLol targets adsorbed to  NT 
TG M~ 
BCG Me +  membranes of RLol  targets absorbed to  NT 
BCG Mr/, 
BCG Me +  membranes of P815 targets  4.5 ±  0.4 
BCG M~ +  membranes of P815  targets absorbed to  NT 
TG M~ 
BCG Mck +  membranes of P815  targets absorbed to  NT 
BCG MO 
x  10' 
23.8 ±  2.8  24.3  ±  3.1  27.8  ±  1.8 
24.0±2.1  24.3± 1.5  27.0±2.1 
25.3::t:3.2  25.8± 1.0  26.3+2.0 
25.0± 1.8  26.5+  1.9  23.5±2.4 
12.0 ±  1.1  8.3:1:2.1  13.5  ±  1.8 
12.8±0.9  11.3±2.9  15.0±  1.1 
21.8±3.1  20.8± 1.4  24.0±2.1 
11.3 ±  0.4  11.3 ±  0.3  16.5  ± 0.5 
12.0 ± 0.9  12.8  ±  1.2  19.5  +  1.2 
19.8 ±  1.3  20.3  ±  2.1  25.0  ±  1.4 
14.3 :t: 1.5  10.5  ±  1.2  12.0  ±  1.2 
13.5 ::1:2.0  15.0  ±  0.5  15.0  ±  1.0 
20.8±  1.2  21.3± 1.4  23.5+  1.9 
* Cultures of purified cultures of BCG-activated or TG-elicited macrophages (BCG  Mq~ and TG  MO, 
respectively) were established at a density of 2.5 X  105 macrophages/cm  2 as described in Materials and 
Methods. A limiting amount of membrane preparation (50 #g of membrane) was then added to each 
well.  After  1 h,  the macrophage cultures  were washed to  remove the nonadherent portions of the 
membrane preparations. These portions were then pooled, pelleted by centrifugation, resuspended in 
fresh medium, sonicated, and finally added to additional cultures of BCG M¢ as described in Materials 
and Methods. The resuspensions were performed so that the residual  portion from one adsorption well 
(i.e., the residuum of 50 #g of adsorbed membrane) was added to one well of macrophages. After 1 h, the 
macrophage cultures were washed and then challenged with 7.5 ×  104 5tCr-labeled  lymphocytes, EL-4, 
RLol, or P815 targets.  The number of targets bound to the BCG Mq~ was quantified 1 h later. 
¢ Targets used for challenge. Number of targets bound in thousands (mean ±  SEM). Percent inhibition as 
compared with medium control. Similar results obtained in two additional experiments. 
§ Not tested. 
and  currently  appears  to  be  best  correlated  with  neoplastic  transformation  of the 
targets and, specifically, with acquisition of the capacity to  form tumors  in  vivo in 
compromised hosts (22, 23). Also, activated macrophages move to, cluster about, and 
interact vigorously with the surfaces of neoplastic targets when observed by cinemi- 
crography  (9-11).  These observations have led to the speculation that susceptibility 
to lysis by activated macrophages relates to changes in the surface of neoplastic cells 
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TAnLE  III 
Effect of Membrane Preparations on Target Cytolysis by BCG-activated Macrophages* 
83 
Added to wells:l: 
Cytolysis of bound targets (percent inhibiton of cytolysis)§ 
Lym- 
pho- 
cytesl[ 
R Lo  I  EL4  P815 
BCG Mck + medium  0 
BCG M~k + membranes of lymphocyte  0 
targets 
BCG Mck + membranes of RLol targets  3 +  1% 
BCG M~ + membranes of EL-4 targets  0 
BCG M~k + membranes of P815 targets  3 ±  1% 
36± 1%  35± 1%  55±3% 
34 ± 2% (-6)  37 ± 2% (+6)  54 ± 2% (-2) 
15± 1% (--58)  20± 1% (-43)  27+.4% (--51) 
8± 1% (--78)  18± 1% (-49)  30+ 1% (--45) 
20 +  1% (--44)  16 :t: I% (--54)  24 ±  1% (--56) 
* The degree of target cytolysis cannot be compared with that previously described  (14), because  the 
present experiments were conducted under endotoxin-depleted  conditions (see Materials and Methods). 
BCG-activated  macrophages  (BCG M#)  (2.5 X  105 macrophages/cm 2) were incubated with 50 #g of 
membrane  preparations from lymphocytes, RLol, El-4, or P815 targets.  After 1 h,  the nonadherent 
membranes were removed and the cultures washed. 7.5 ×  104 labeled targets were added to the cultures. 
1 h later, unbound targets were removed. After 18 h, the net cytolysis of the bound targets was determined 
as described in Materials and Methods. 
§ Percent net cytolysis (mean + SEM). Percent inhibition as compared with medium control. The data on 
cytolysis in  this  Table were obtained in  the same  experiment  presented  in  Table I.  Similar results 
obtained in three additional experiments. 
]] The cytolysis of lymphoblasts by BCG Mqa under these conditions, in two similar experiments, was 1.0% 
and 0%. The extent of binding of these lymphoblasts is given in Table I, footnote §. 
Activated macrophages  have  recently been  found  to  bind  neoplastic target  cells 
with  a  selectivity that  mimics that  observed in  macrophage-mediated cytolysis (12, 
13).  Observations  from  this  laboratory showed  that  activated murine  macrophages 
extensively and selectively bound any of six neoplastic murine targets but not any of 
three nonneoplastic targets (13).  The binding to the surface of the activated macro- 
phages requires living, metabolically active macrophages and the presence of trypsin- 
sensitive structures on the macrophages (12,  13). Of interest, H-2 differences between 
murine  macrophages  and  targets were  not  necessary for such  binding and  did not 
prevent it (13). Subsequent observations showed that binding of neoplastic targets to 
BCG-activated macrophages is an initial and necessary step in cytolysis (14,  15). The 
binding of neoplastic targets  to  activated macrophages  may  thus  be  a  part  of the 
recognition system  by which  activated macrophages  distinguish between  neoplastic 
and nonneoplastic cells for subsequent cytolysis. 
The  present  observations  demonstrate  that  membrane  preparations  from  three 
disparate murine tumors  (i.e., a  lymphoma, a  leukemia, and a  mastocytoma) inhibit 
binding  of the  homologous  targets  to  BCG-activated  macrophages  (Table  I).  The 
inhibition produced by membrane  preparations was  dose-dependent,  and  >80%  of 
target binding could be abrogated by increasing the amount of membrane preparation 
added to the macrophages (Fig. 1 A). By contrast, comparable amounts of membrane 
preparations of lymphocytes did not appreciably inhibit binding of any of the three 
neoplastic targets to BCG-activated macrophages (Table I). This implies some degree 
of selectivity in the inhibitory action of membrane preparations, and would appear to 
exclude trivial explanations of inhibition such as toxicity to the macrophages because 
of the technique of preparing the membranes or nonspecific inhibition because of the 84  EFFECT  OF MEMBRANES ON  TARGET BINDING BY  MACROPHAGES 
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FIG. 2.  Dose-response  of inhibitory activity of preparations enriched in plasma membranes from 
EL-4 targets on binding  of P815 and of EL-4 targets to BCG-activated macrophages. Enriched and 
crude membranepreparations  from EL-4 targets were added to the macrophage cultures (2.5 ×  105 
macrophages/cm  ~) over a range of concentrations (2-25/×g/well and 10-120  btg/well, respectively). 
After 1 h, the cultures were washed to remove all nonadherent membrane fragments. Control wells, 
to which no membranes were added, were similarly washed. The cultures were then challenged 
with 7,5 ×  10451Cr-labeled  P815 or EL-4 targets. The number of P815 or EL-4 targets bound after 
i h of cocultivation was then quantified. In control wells, 30.8 -I- 2.8 X 103 and 25.5 ±  3.1  X 103 
P815 and EL-4 targets, respectively, were bound to the  macrophages; data were plotted  as a 
percentage of the binding  to those control wells. Binding in cultures treated with plasma membranes 
is shown by the two responses at the extreme left, whereas binding in cultures treated with crude 
membrane preparations is shown by the two responses which extend to the extreme right. Similar 
data were obtained in an additional experiment. 
amount of protein added. Of particular interest, membrane preparations from RLol, 
EL-4,  P815  targets  also  inhibited binding of heterologous  targets  (Table  I).  The 
membrane-associated property  responsible  for  inhibition of binding may  thus  be 
shared between the RLol, EL-4, and P815 tumor cells. Membrane preparations from 
these three targets also inhibited cytolysis of both the homologous and heterologous 
targets  (Table  III).  Previous observations have  shown  that  intact  P815  and  EL-4 
targets inhibit subsequent binding and cytolysis of the homologous and heterologous 
targets  (14).  This finding is in contrast to observations on the interaction of target 
membranes or isolated portions thereof with cytolytic T  lymphocytes; these prepara- 
tions have been observed, with one exception, to inhibit lymphocyte-target binding, 
but not to inhibit subsequent target cytolysis (20, 25-27). The inhibitory activity of 
the  membranes was  enhanced  =8  to  10-fold  in  preparations  enriched  in  plasma 
membranes (Fig. 2). The data suggest that the binding of three nonadherent murine 
tumor cells to BCG-activated macrophages is mediated, in part, by plasma membrane- 
associated recognition structures that are apparently common to the three neoplastic 
targets examined but not to normal murine lymphocytes and lymphoblasts. 
The binding of various cells to  macrophages  is of two  general sorts.  The first, a 
selective and saturable binding of high degree, is observed between activated macro- 
phages and tumor cells (13). This binding has two functional consequences: cytolysis 
of the  bound targets  (14)  and  enhanced secretion  of a  cytolytic proteinase.  2 The 
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second, a  nonselective and nonsaturable binding of low degree, is observed between 
lymphocytes and activated macrophages or between tumor cells and resident macro- 
phages,  inflammatory maerophages,  other  tumor  cells,  and  embryonic fibroblasts 
(13). To date, a functional consequence of this type of binding has not been identified 
(14).  We here report  that binding of the first type was inhibited by membranes of 
tumor cells, whereas  binding of the second  type was  not  (Table  I).  Furthermore, 
inhibitory activity of membranes from tumor cells could be adsorbed by passage over 
BCG-activated macrophages, but not over TG-elicited macrophages (Table II). Taken 
together, these observations raise the possibility that macrophage-target binding, like 
ligand-receptor binding,  may be  divided into specific and nonspecific components 
(28). This possibility is strengthened by the observation that membrane preparations 
of tumor cells reduced  the  number of targets required  for saturation  but  did not 
abrogate saturation (Fig. 1 B). 
The  basis  of binding between  activated  macrophages  and  neoplastic  targets  is 
clearly open to multiple possible explanations. The molecular constituents of mem- 
branes  of neoplastic  cells  differ both  quantitatively and  qualitatively  from  their 
normal counterparts in many regards (reviewed in [29-32]).  As just one type of such 
change, membranes of tumor cells have been reported to differ in the expression of 
several  glycopeptides and  of specific  glyeoproteins (33,  34).  The  increased lateral 
mobility of membrane constituents such as receptors and antibody-binding sites in 
neoplastic cells (29, 31) might further complicate the matter. Furthermore, recognition 
might not be confined solely to perception of differences in molecular constituents 
between neoplastic and nonneoplastic membranes; rather, recognition might involve 
perception of differences in the spatial arrangement of such constituents as well. Our 
observations suggest that membranes of three murine tumor cells share membrane- 
associated recognition structures that mediate the binding of those targets to BCG- 
activated macrophages. This observation and the experimental system described here 
may  provide  tools  for  analyzing further  the  basis  of binding  between  activated 
macrophages and neoplastic cells. 
Summary 
The binding of tumor cells by activated macrophages is an initial and necessary 
event  in  the  cytolysis  of these  targets.  The  data  here  indicate  that  membrane 
preparations from RLal  leukemia targets, EL-4 lymphoma targets, and P815 mas- 
tocytoma targets each inhibited binding of its homologous target to bacillus Calmette- 
Gu~rin  (BCG)-activated murine macrophages in a  dose-dependent fashion. Similar 
amounts of membrane from lymphocytes did not alter binding of the three neoplastic 
targets to BCG-macrophages. Membranes of the three targets also inhibited binding 
of the heterologous neoplastic targets. Inhibitory activity of membrane preparations 
from  P815,  EL-4, and  RLal  targets could be  adsorbed  by incubation of limiting 
concentrations of the membrane preparations with BCG-activated macrophages but 
not with thioglycollate broth-elicited macrophages. Exposure of BCG macrophages to 
membrane  preparations  from  RLal,  EL-4,  or  P815  targets  inhibited  subsequent 
cytolysis of the three targets. Inhibitory activity was increased in preparations enriched 
for plasma membrane. The data suggest that binding of three murine, nonadherent 86  EFFECT OF MEMBRANES  ON  TARGET BINDING  BY  MACROPHAGES 
neoplastic  targets  to  BCG-activated  murine  macrophages  is  mediated,  in  part,  by 
recognition structures present within the plasma membranes of the three targets. 
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